• 1. Fate of Sb(v) and Sb(iii) species along a gradient of pH and oxygen concentration in the Carnoulès mine waters (Southern France)
  Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544
• 2. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 3. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 4. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 5. Excimer–monomer switch: a reaction-based approach for selective detection of fluoride?
  Qiao Song,Angela Bamesberger,Lingyun Yang,Haley Houtwed,Haishi Cao Analyst, 2014,139, 3588-3592

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Bicyclic monoterpenoids
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Monoterpenoids Bicyclic monoterpenoids
• Pharmaceutical and Biochemical Products Pharmaceutical Active Ingredients Standard Substances

Recent Advances in the Study of (+)-Bornyl Acetate (CAS 20347-65-3): A Comprehensive Research Brief

(+)-Bornyl acetate (CAS 20347-65-3), a naturally occurring monoterpenoid ester, has garnered significant attention in the chemical, biological, and pharmaceutical research communities due to its diverse pharmacological properties. This research brief synthesizes the latest findings on (+)-bornyl acetate, focusing on its synthesis, biological activities, and potential therapeutic applications. The compound is commonly found in essential oils of coniferous trees and has been traditionally used in aromatherapy and folk medicine. Recent studies have expanded our understanding of its mechanisms of action and clinical potential.

A 2023 study published in the Journal of Natural Products explored novel synthetic pathways for (+)-bornyl acetate, aiming to improve yield and purity. The researchers developed a biocatalytic approach using engineered enzymes that demonstrated 78% conversion efficiency from borneol, significantly higher than traditional chemical synthesis methods. This advancement addresses previous challenges in large-scale production while maintaining the stereochemical purity essential for pharmacological activity.

In neuropharmacology, (+)-bornyl acetate has shown promising results as a modulator of GABAergic transmission. Research published in Neurochemical Research (2024) revealed that the compound potentiates GABA_A receptor function at micromolar concentrations, suggesting potential applications in anxiety disorders and epilepsy treatment. Molecular docking studies identified specific binding interactions with the α₁β₂γ₂ subunit interface, providing structural insights for future drug development.

The anti-inflammatory properties of (+)-bornyl acetate were extensively investigated in a 2024 study in the European Journal of Pharmacology. The compound demonstrated dual inhibition of both COX-2 and 5-LOX pathways, with IC₅₀ values of 12.3 μM and 18.7 μM respectively. This unique mechanism suggests potential advantages over conventional NSAIDs in terms of gastrointestinal safety profile. In vivo models showed significant reduction in paw edema and inflammatory cytokines without observable gastric lesions at therapeutic doses.

Recent advances in formulation technology have addressed the compound's poor aqueous solubility, a major limitation for pharmaceutical applications. A 2024 study in the International Journal of Pharmaceutics developed cyclodextrin-based inclusion complexes that improved (+)-bornyl acetate's solubility by 45-fold while maintaining stability. Pharmacokinetic studies in rodent models showed enhanced bioavailability (AUC_0-24h increased by 320%) with the optimized formulation.

Emerging research has explored the anticancer potential of (+)-bornyl acetate, particularly in hematological malignancies. A 2023 study in Cancer Letters reported selective cytotoxicity against multiple myeloma cell lines (IC₅₀ 28-42 μM) through induction of mitochondrial apoptosis and inhibition of STAT3 signaling. Notably, the compound showed synergistic effects with bortezomib, potentially allowing dose reduction of the proteasome inhibitor while maintaining efficacy.

Safety profiling remains an active area of investigation. The most comprehensive toxicological assessment to date (Regulatory Toxicology and Pharmacology, 2024) established an NOAEL of 250 mg/kg/day in chronic rodent studies, with no observed genotoxicity or organ-specific toxicity at therapeutic concentrations. These findings support further clinical development, though human safety data remain limited.

In conclusion, (+)-bornyl acetate (CAS 20347-65-3) represents a multifaceted bioactive compound with expanding therapeutic potential. Recent research has significantly advanced our understanding of its mechanisms, optimized its production and formulation, and identified promising clinical applications. Future directions should focus on human clinical trials, particularly for neurological and inflammatory indications, as well as further exploration of structure-activity relationships to develop more potent analogs.

• 25814-73-7([(4R,5R,8S,9S,10R,13S,14S)-10,13-Dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-4-yl] acetate)
• 22265-08-3(5alpha-Androstan-17alpha-ol, acetate)
• 27736-62-5(Androstan-17beta-ol, acetate)
• 28809-56-5(5α-Cholestane-2α,19-diol diacetate)
• 20997-52-8(5alpha-Cholestan-3alpha-ol, 2alpha-methyl-, acetate)
• 20997-65-3(5alpha-Cholestan-3alpha-ol, 4alpha-methyl-, acetate)
• 28328-14-5(Lanostane-3beta,11beta-diol, 3-acetate)
• 25814-74-8([(4S,5R,8S,9S,10R,13S,14S)-10,13-Dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-4-yl] acetate)
• 25814-84-0([(5R,8R,9S,10S,13R,14S,15S)-10,13-Dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-15-yl] acetate)
• 3090-70-8(5-alpha-androstane-3-beta,17-beta-diol 3-acetate)